Biocomposites' geneX cleared for use in China

US privately-held firm Biocomposites says that its bone graft substitute geneX has been cleared for use by China's State Food and Drug  Administration.

geneX is a synthetic bone graft material with a unique bi-phasic  composition, manufactured through a proprietary process that confers the  product with a reproducible negative surface charge. This property  stimulates bone cell activity, accelerating bone formation and fusion by  harnessing key proteins and directing osteoblast adhesion and  proliferation for rapid osteogenesis. geneX is fully resorbable and is  completely replaced by bone.

Commenting on the clearance, Simon Zhou, general manager of  Biocomposites (Shanghai) Ltd, said: "in the fast-growing Chinese market,  surgeons and patients can now take full advantage of the significant  benefits that geneX brings over traditional bone graft substitutes."